Cardiomyocytes are resistant to radiation. However, cardiac radiation exposure causes coronary microvascular endothelial inflammation, a perturbation implicated in the pathogenesis of heart failure (HF) and particularly HF with preserved ejection fraction (HFpEF). Radiotherapy for breast cancer results in variable cardiac radiation exposure and may increase the risk of HF.
B
reast-conserving surgery plus radiotherapy has emerged as the standard approach for localized breast cancer, and in more advanced disease, radiotherapy improves local control and survival. [1] [2] [3] [4] The high doses of thoracic radiation used with thoracic tumors and older breast cancer radiotherapy techniques increase the risk of cardiac disease. [5] [6] [7] [8] Advances in radiotherapy planning, including the use of computed tomography (CT)-assisted radiotherapy planning, can substantially reduce cardiac radiation exposure during contemporary breast cancer radiotherapy. 5 However, even low levels of cardiac radiation during breast cancer radiotherapy increase the risk of coronary events. 6 Cardiomyocytes are resistant to radiation. However, radiation induces coronary microvascular endothelial damage and inflammation, leading to microvascular rarefaction and myocardial inflammation, oxidative stress, and fibrosis. [7] [8] [9] [10] Comorbidity-driven coronary microvascular endothelial inflammation with similar subsequent myocardial effects has been implicated as a key factor in the pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF). 11, 12 Although major cardiomyocyte loss due to infarction or other factors is the primary etiologic insult in HF with reduced ejection fraction (HFrEF), comorbidity-driven coronary microvascular endothelial inflammation can contribute to global myocardial dysfunction and HF progression. 11, 12 Accordingly, we hypothesized that cardiac radiation exposure during contemporary breast cancer radiotherapy may increase the risk of HF and particularly HFpEF. We performed a population-based case-control study of patients with breast cancer treated with CT-guided radiotherapy, relating the odds of incident HF after radiotherapy to mean cardiac radiation dose (MCRD) and HF risk factors.
METHODS Study Population
This study was restricted to appropriately consented residents of Olmsted County, Minnesota. The study was approved by the Institutional Review boards of the Mayo Clinic and the Olmsted Medical Center.
For Olmsted County residents, radiotherapy is provided solely by the Mayo Clinic. Using the resources of the Rochester Epidemiology Project and the Mayo Clinic Cancer Registry (Methods in the online-only Data Supplement), we identified all female patients >18 years of age who had undergone radiotherapy for a histologically proven diagnosis of breast cancer in the era when CT-guided radiotherapy planning was beginning to be integrated into clinical practice (January 1998-December 2013) and who resided in Olmsted County at the time of and after radiotherapy ( Figure I in the online-only Data Supplement). The date of first appearance of diagnostic codes for HF and relevant comorbidities ( Table I in the online-only Data Supplement) was extracted for all patients. Patients with an HF diagnosis, thoracic radiation, or chemotherapy before the breast cancer diagnosis date were excluded from consideration as cases or controls.
We manually reviewed the medical records of patients with an HF diagnostic code to further confirm the absence of preexisting HF or cardiomyopathy and to determine whether patients met the modified Framingham criteria for HF 13 (Table II in the online-only Data Supplement) or if a physician had indicated a diagnosis of HF in the medical record with supportive clinical symptoms, signs, and chest radiograph or echocardiographic evidence of HF (Table III in the online-only Data Supplement) . Patients with other explanations (ie, lung metastasis) for HF symptoms were excluded. The medical records of potential controls were also reviewed with the use of free text data searches of the electronic medical record for terms consistent with HF (Methods in the online-only Data Supplement). If such terms were present, charts were manually reviewed to confirm HF as above. Assessment for incident HF included the interval from breast cancer diagnosis through December 31, 2014.
Cases and controls with bilateral tumors, distant metastases at initial diagnosis, additional radiotherapy, or chemotherapy after their initial breast cancer treatment or who did not have CT-based radiotherapy planning were excluded. At least 1 and up to 2 radiated breast cancer controls corresponding to each HF case were matched for factors known to increase HF risk, including age at the breast cancer diagnosis (within 10 years), use of anthracycline, use of trastuzumab, and history of hypertension or diabetes mellitus. Because the cardiac chambers exposed to radiation may vary by tumor side, we also matched by tumor side. 14, 15 Controls were required to have follow-up (index interval) equivalent to or greater than the time from radiotherapy to HF diagnosis of the corresponding case.
Comorbid conditions, cardiovascular medications, lifestyle information, and cardiac imaging data were extracted from the
Clinical Perspective
What Is New?
• In this population-based case-control study of older women with breast cancer treated with contemporary conformal radiotherapy, the odds of incident heart failure (HF) after radiotherapy increased with higher mean cardiac radiation dose.
• The predominant form of HF was HF with preserved ejection fraction (≥50%) or HF with midrange (40%-49%) ejection fraction.
• The relative risk for any HF and for HF with preserved ejection fraction increased with mean cardiac radiation dose, even after adjustment for other known risk factors and cancer stage. • Myocardial infarction caused by epicardial coronary disease was not the predominant mediator of incident HF.
What Are the Clinical Implications?
• These data emphasize the importance of radiotherapy techniques that limit mean cardiac radiation dose during breast cancer treatment.
• Moreover, these data provide further support for the importance of coronary microvascular compromise in the pathophysiology of HF with preserved ejection fraction.
medical record. The presence of ischemic heart disease was defined as a history of myocardial infarction, coronary bypass grafting, or percutaneous coronary intervention and ascertained as previously described. 16 Availability of EF measurement at the time (30 days before or after) of HF diagnosis was assessed and used to characterize HF as HFpEF (≥50%), HFrEF (<50%), or HF with indeterminate (unavailable) EF.
Higher cancer stage often mandates more extensive radiotherapy and increases MCRD but also may result in heightened surveillance and bias HF ascertainment. Thus, we performed a sensitivity analysis rematching controls to cases using the same criteria as above except matching for cancer stage rather than tumor side (Methods in the online-only Data Supplement).
Breast Cancer Treatment and Dosimetry
Breast cancer characteristics and treatment, including the use of systemic therapy and details of radiation therapy, were extracted from Mayo Cancer Registry database and radiation oncology record and by manual record review. In each patient, MCRD was calculated with simulation software (Eclipse, Varian Medical System, Inc, Palo Alto, CA) integrating the patient's complete chest CT image set and the radiotherapy plan (Methods in the online-only Data Supplement). Dose-sparing techniques were integrated over the study period (Methods in the online-only Data Supplement).
Statistical Analyses
Conditional logistic regression, conditioning on the matching factors (age, tumor side, chemotherapy use, diabetes mellitus, and hypertension), was used to estimate incident HF odds ratios associated with clinical characteristics not used to match cases and controls. Similar models were used to calculate incident HF (overall and by HF type) odds ratios per (natural) log MCRD. Odds ratios were estimated without or with adjustment for clinical characteristics not used as matching factors but associated with HF incidence by including these adjustment factors as covariates in the conditional logistic regression models. The natural logarithm of MCRD was applied before analyses because of the skewed distribution of MCRD; this transformation improved model fit and lowered the potential of influential observations with very large values. Because the age-matching criterion was fairly broad, we also performed analysis adjusting for age as a continuous variable. Interaction terms were added to the models to test for differences in dose effects and time to HF onset.
Comparisons of crude HF frequency (HF or no HF) with increasing MCRD category were analyzed with the CochranArmitage test for trend. Significance tests were 2 sided. A value of P<0.05 was considered statistically significant. Calculations were performed with the use of SAS version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS

Characteristics of the Study Patients
Among 945 female Olmsted County residents with breast cancer who underwent radiotherapy during 1998 to 2013 (median age, 59 years), we identified 77 patients who developed new-onset validated HF after radiotherapy. Of these 77 potential cases, 60 met final entry criteria ( Figure I in the online-only Data Supplement). No matching control was found for 1 case; only 1 matching control was found for 7 cases; and 2 matching controls were found for 52 cases. Thus, the study included 59 HF cases and 111 controls without HF. Of the HF cases, 43 fulfilled Framingham criteria, and the remaining 16 had a physician's diagnosis of HF recorded in the medical record with objective evidence of HF (Table III in the online-only Data Supplement). Of HF cases, 38 (64%) had HFpEF, 18 (31%) had HFrEF, and 3 (5%) did not have EF measured coincident with HF diagnosis. Of note, the EF was ≥40% in 50 of the 56 HF cases (89%) with an EF measurement. The majority of cases (57, 97%) and controls (105, 97%) were white. The mean interval from radiotherapy to HF diagnosis and corresponding index interval in controls was 5.8±3.4 years. Matched characteristics were similar in cases and controls ( Table 1) . The relative risk of HF was higher in patients with more advanced cancer stage and in those with a history of ischemic heart disease or atrial fibrillation ( Table 1) .
Impact of MCRD on the Relative Risk of Incident HF
The overall MCRD was 2.5 Gy (range, 0.2-13.1 Gy) and higher in cases (3.3±2.7 Gy) than controls (2.1±2.0 Gy; P=0.004; Figure 1 ). The average MCRD was higher in women with left-sided (4.1 Gy; range, 0.6-13.1 Gy) versus right-sided (1.5 Gy; range, 0.2-5.6 Gy; P<0.001) tumors (Figure 1, inset) . The MCRD was higher in patients with higher cancer stage ( Figure II in the onlineonly Data Supplement), likely owing to internal mammary node treatment. In the entire study population, tumor side explained 37% (P<0.001) of the variation and tumor side and cancer stage together explained 44% (P<0.001 for both) of the variation in MCRD. MCRD decreased over the study era ( Figure III in the online-only Data Supplement).
The crude frequency of HF cases versus controls increased with higher MCRD (Figure 2 ). The odds of incident HF (any) and of HFpEF increased with higher MCRD (Table 2 ), even after adjustment for age, cancer stage, and history of ischemic heart disease or atrial fibrillation. The crude frequency of HF at any MCRD was numerically higher in those with versus those without a history of ischemic heart disease or atrial fibrillation, but the crude HF frequency increased with increasing MCRD in both groups ( Figure 3 ) as in the overall conditional regression analysis ( Table 2 ). The effect of MCRD on the odds of incident HF was apparent and statistically significant in patients with left-or right-sided tumors (Table IV in the online-only Data Supplement). Furthermore, consistent with our findings matched by use of chemotherapy (Table 2) , the crude frequency of HF increased with MCRD when the analysis was restricted to patients not receiving chemotherapy ( Figure IV in the online-only Data Supplement). The odds of incident HFrEF increased with higher MCRD, but this association was not significant ( Table 2) . After adjustment for age, HF risk factors, and cancer stage, there was no difference in the association between MCRD effect and odds of HF by time from radiotherapy (interaction radiation dose×time P=0.61; Table 3 ).
Sensitivity Analyses
In a cohort matched by the same factors except cancer stage rather than tumor side, clinical characteristics associated with HF incidence (Table V in the online-only Data Supplement) were similar to those in the primary analysis. The MCRD was associated with HF and HFpEF incidence (Table VI in the online-only Data Supplement), even after adjustment for pertinent covariates. The magnitude of odds per log MCRD was lower than in the primary analysis but remained substantial, particularly if the analysis was adjusted for tumor side. The effect of MCRD on the odds of incident HF was apparent and statistically significant when patients who did not fulfill Framingham criteria for HF diagnosis were excluded both in the primary analysis cohort matched by tumor side (Table VII in 
Factors Associated With Development of HF After Radiotherapy
Of patients who developed HF after radiotherapy, 11 (18.6%) had new or recurrent ischemic heart disease events, 15 (25.4%) had new or recurrent atrial fibrillation, and 22 (37.3%) had either of these conditions after radiotherapy but before or coincident with the HF diagnosis.
DISCUSSION
In this population-based case-control study of older women with breast cancer treated with contemporary conformal radiotherapy, the odds of incident HF after radiotherapy increased with higher MCRD. The predominant form of HF was HFpEF or HF with midrange (40%-49%) EF, 17 and the odds for any HF and for HFpEF increased with MCRD, even after adjustment for other known risk factors and cancer stage. The mean time from radiotherapy to HF was 5.8 years. A minority of women developed ischemic events between radiotherapy and HF diagnosis, suggesting that myocardial infarction due to epicardial coronary disease was not the predominant mediator of incident HF. The effect of MCRD on HF incidence was still apparent in sensitivity analyses addressing the potential for surveillance bias associated with higher cancer stage.
In 40-year-old women, the lifetime risks of both breast cancer (12%) and HF (20%) are significant. 18, 19 Adjuvant Figure 1 . Distribution of mean cardiac radiation dose in study patients.
The mean cardiac radiation dose in cases and controls and in patients with right-or left-sided tumors (inset) is shown. ACE indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; and CI, confidence interval. Ischemic heart disease was defined as a history of myocardial infarction, coronary bypass grafting, or percutaneous coronary intervention before breast cancer diagnosis. radiotherapy reduces breast cancer loco-regional recurrence and mortality in some breast cancer subgroups.
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The excellent survival after treatment for localized breast cancer mandates attention to survivorship issues, including cardiovascular complications of radiotherapy. 20 The risk of cardiac toxicity with high-dose thoracic radiotherapy is well documented. 2, 7, 8, 10, 20 Although MCRD varies with tumor side and treatment of nodal beds, individual variation in thoracic and cardiac anatomy contributes significantly to cardiac exposure, as seen here. Thus, although on average MCRD is quite low with contemporary conformal breast cancer radiotherapy, significant individual variation exists. 5, 14, 15 A growing number of radiotherapy techniques can reduce cardiac exposure, 5 but they are inconsistently used. Indeed, average cardiac doses and, importantly, maximal cardiac doses in a meta-analysis of contemporary breast cancer radiotherapy studies substantially exceed those observed here. 5 Furthermore, even as MCRD falls with improved techniques, our data emphasize that women treated before such advances remain at increased risk of HF. The present data also underscore the need to reduce MCRD, particularly in older women with HF risk factors.
Consistent with our findings, the ongoing study of atomic bomb survivors in Japan has demonstrated that total body radiation exposures of <2.5 Gy leads to significant increases in the incidence of HF (excess risk, 22% per 1 Gy) but not myocardial infarction. 7 Meta-analyses have suggested that cardiovascular mortality and some assessed cardiovascular morbid events are not increased in women treated with more contemporary breast cancer radiotherapy techniques. 20, 21 However, these studies acknowledge the limited follow-up duration, the lack of individual cardiac dose data, and importantly, the potential for interaction between preexisting clinical or subclinical cardiovascular abnormalities and the impact of cardiac radiation dose. 20, 21 Beyond differences in therapeutic era, the designs of studies assessing radiotherapy cardiac toxicity have varied, and comparisons between patients with breast cancer with or without radiotherapy and between patients receiving left-or right-sided tumor radiotherapy have significant limitations resulting from confounders 6 and the inability of tumor laterality to precisely reflect individual cardiac dose, as also demonstrated here. To address these limitations, Darby et al 6 used a case-control design with estimations of individual-patient MCRD derived from AF indicates atrial fibrillation/flutter; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IHD, ischemic heart disease; and MCRD, mean cardiac radiation dose.
the radiotherapy treatment plan and a single "representative" CT scan. Even after adjustment for coronary risk factors, the risk of major coronary events increased in proportion to the MCRD (7% per 1 Gy) and over a fairly short interval after radiotherapy. The absolute risk was highest in older women with coronary risk factors.
The present study used a case-control design rather than a cohort study design. Results from previous cohort studies of the effect of breast cancer radiotherapy on HF incidence have been mixed. [22] [23] [24] [25] No study has specifically examined the effect of individually calculated MCRD on the incidence of HFpEF and HFrEF, and study designs were subject to the limitations noted above and complexities of HF (and particularly HFpEF) case ascertainment. 26 The incidence of HF increases dramatically with age, and in the community, the mean age at HF diagnosis is 78 years for HFpEF and 72 years for HFrEF. 27 Given the average age (61 years) and low MCRD in the majority of contemporary patients with breast cancer, 5, 15 the likely critical interaction between the impact of MCRD and preexisting age-and comorbidity-related myocardial abnormalities, the underuse of radiotherapy in older patients with HF risk factors, 28, 29 and the challenges in HF case ascertainment, a general breast cancer cohort study may fail to detect the impact of radiation dose on HF incidence without accurate cardiac dose assessment and sensitive case ascertainment methodology.
Several studies have documented new cardiac perfusion defects (without interim myocardial infarction) after breast cancer radiotherapy consistent with microvascular rarefaction. 30 Comorbidity-driven coronary microvascular endothelial inflammation is believed to play a key role in the pathophysiology of HFpEF. Microvascular endothelial inflammation leads to microvascular dysfunction and rarefaction with a reduction in coronary flow reserve and myocardial inflammation and fibrosis, as well as oxidative stress, which may impair nitric oxide-cGMP signaling and potentiate cardiomyocyte hypertrophy and myofiber diastolic stiffness. 11, 12, 31 The mechanism of radiation-induced myocardial disease is well described, with microvascular damage leading to inflammatory and thrombotic changes, microvascular rarefaction, myocardial inflammation, oxidative stress, and fibrosis, as well as focal ischemia. 4, 6, 7, 20 Thus, the present findings are consistent with and lend further support to the pivotal role of the microvasculature in the pathophysiology of HFpEF, 31, 32 for which microvascular inflammation has been histologically demonstrated. 33 Studies of heart disease after higher doses of cardiac radiation in younger patients 7 suggest that HF is a late occurrence. However, older women receiving breast cancer radiotherapy have comorbidities and may already have significant but subclinical coronary microvascular and myocardial disease. Thus, even low doses of cardiac radiation may have an impact, providing the further disruption in microvascular structure and function required to precipitate overt HF.
Potential Limitations and Strengths
The study size was small, but the design was strengthened by the use of precise MCRD calculation using the complete set of CT images, matching or adjusting for HF risk factors, complete patient level data, rigorous case ascertainment techniques, the community-based set- Figure 3 . Crude frequency of heart failure (HF) cases vs controls according to category of mean cardiac radiation dose (MCRD) and stratified by history of HF risk factors before breast cancer diagnosis.
HF cases (red) relative to controls (blue) increased with increasing MCRD regardless of the presence or absence of atrial fibrillation (AF) or ischemic heart disease (IHD) before breast cancer diagnosis. ting, and our sensitivity analyses. Few women developed HFrEF, and even among the HFrEF group, most had midrange EF (40%-49%), 17 often considered to be HFpEF, and thus the impact of MCRD on HFrEF incidence is uncertain. Restriction to the contemporary therapeutic era limits the ability to detect longer-term risks in younger women. Specific cardiac chamber doses were not assessed and may be important 14 because impairment in both atrial and right ventricular function contributes to the pathophysiology of HFpEF. 34, 35 Although the analysis adjusted for nonmatched variables associated with HF (ischemic heart disease and atrial fibrillation), we cannot exclude residual confounding, but the effect of dose on crude HF odds ratios in patients with or without these risk factors was still apparent. Although we confined our analysis to the era when CT-guided radiotherapy planning was beginning to be integrated into clinical practice, this was an incremental practice change, and not all patients receiving radiotherapy had CT scans for MCRD calculations.
Conclusions
In older women undergoing contemporary breast cancer radiotherapy, the relative risk of HFpEF increases in proportion to calculated MCRD, begins within a few years after radiotherapy, and is not mediated solely by coronary events. These data suggest that cardiac dose and HF risk factors should be considered in decisions about breast cancer radiotherapy and underscore the importance of techniques for reducing cardiac dose. Moreover, these data provide further support for the importance of coronary microvascular compromise in the pathophysiology of HFpEF. 
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